Regeneron price target raised to $1,110 from $1,076 at RBC Capital

RBC Capital analyst Brian Abrahams raised the firm’s price target on Regeneron (REGN) to $1,110 from $1,076 and keeps an Outperform rating on the shares. The company’s Dupixent metrics suggest underappreciated near- and long-term growth prospects on the back of the earlier report from partner Sanofi (SNY), while their best-in-class pipeline breadth and depth continues to grow with many shots on large-market oncology, immune, and metabolic indications likely still not reflected much in the stock’s valuation, the analyst tells investors in a research note.